StonvexLoading…
StonvexStonvexStonvexCore line items from CHYM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 |
|---|---|---|---|
Revenue | $2.19B | $1.67B | $1.28B |
Operating Income | $-1.04B | $-62.20M | $-235.78M |
Net Income | $-1.01B | $-25.34M | $-203.20M |
EPS (Diluted) | $-4.27 | $-0.39 | $-3.22 |
Total Assets | $1.96B | $1.46B | Not available |
Total Liabilities | $562.90M | $501.52M | Not available |
Cash & Equivalents | $466.25M | $337.70M | $239.75M |
Free Cash Flow OCF − CapEx | $32.89M | $59.33M | $-167.09M |
Shares Outstanding | 0 | 66.95M | 63.10M |